Table 1.
Patient background characteristics.
| Case | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Age (years) | 84 | 82 | 76 | 78 | 78 |
| Sex | Female | Female | Male | Male | Female |
| Height (cm) | 144.2 | 154.2 | 161.5 | 162.8 | 147 |
| Weight (kg) | 56.5 | 40 | 66.9 | 44.9 | 49.8 |
| BSA (m2) | 1.46 | 1.329 | 1.71 | 1.45 | 1.41 |
| BMI (kg/m2) | 27.2 | 16.8 | 25.6 | 16.9 | 23 |
| Performance status | 0 | 0 | 0 | 3 | 0 |
| Histology | Adeno | Adeno | Adeno | Sarcomatoid carcinoma | Adeno |
| KRAS mutation | G12C | G12C, G13C | G12C | G12C | G12C |
| PD-L1 (22C3) | <1% | 5% | 20% | <1% | <1% |
| Clinical stage | IVA | IVB | IIIC | IVB | IVB |
| Metastasis | Pulmonary | Pulmonary bone | – | Brain, bone, gastric, adrenal gland, skin | Bone |
| Treatment line | 2 | 2 | 2 | 2 | 2 |
| First-line treatment | PEM | PEM | CBDCA+PEM+Pemb | CBDCA+PTX+Pemb | CBDCA+PEM |
| Sotorasib administration period (days) | 211 | 210 | 277 | On-going | 134 |
| PFS (months) | 6.9 | 4 | 9 | 2 | 4.6 |
| OS (months) | 6.9 | 4 | 9 | 2.5 | 5.4 |
| eGFR (mL/min/1.73 m2) | 68 | 54.6 | 47.1 | 95.4 | 35.2 |
| Alb (IU/L) | 3.8 | 3.7 | 4.1 | 3.1 | 3.5 |
| Best overall response | PR | PR | PR | SD | PR |
| Side effects | none | none | interstitial pneumonitis (suspicion of pembrolizumab)Grade 3 | none | nausea/vomiting Grade 2 fatigue Grade 4 |
Adeno, adenocarcinoma; Alb, albumin; BMI, body mass index; BSA, body surface area; CBDCA, carboplatin; eGFR, estimated glomerular filtration rate; KRAS, Kirsten rat sarcoma viral oncogene homologue; OS, overall survival; PD-L1, programmed death-ligand 1; PEM, pemetrexed; Pemb, pembrolizumab; PFS, progression-free survival; PR, partial response; PTX, paclitaxel; SD, stable disease.